Lorenzo Marchetti

Lorenzo Marchetti

Auto-generated profile, based on publicly available information

Lorenzo Marchetti

Department of Digestive Diseases, Campus Bio Medico University of Rome, Roma, Italy

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
19 September 2024 in American Journal of Gastroenterology
Verified
Journal Article
Closed access
CGC. Prakash Gyawali
C. Prakash Gyawali
LMLorenzo Marchetti
Lorenzo Marchetti
BRBenjamin D. Rogers
Benjamin D. Rogers
WCWalter W. Chan
Walter W. Chan
MWMing-Wun Wong
Ming-Wun Wong
JPJohn Pandolfino
John Pandolfino
INTRODUCTION: We explored if a score derived from parameters from esophageal testing could increase confidence in diagnosing conclusive gastroesophageal reflux disease and in predicting outcome. METHODS: A prediction score was developed using metrics based on Lyon Consensus 2.0 thresholds extracted from endoscopy and pH-impedance monitoring. The Lyon score was the sum of weighted scores derived from a logistic regression model. The outcome was response to antireflux therapy, defined as 50% reduction in global symptoms on validated questionnaires. An existing database of endoscopy-negative patients with typical reflux symptoms undergoing esophageal testing from 2 centers (Europe and the United States) constituted the developmental cohort, while 2 separate cohorts (Europe and Asia) served as validation cohorts. Receiver operating characteristics analysis determined performance of the Lyon score in predicting treatment response. RESULTS: In 281 developmental cohort patients (median age 53 years, 57.7% female), the Lyon score demonstrated an area under the curve (AUC) of 0.819 in predicting 50% symptom improvement ( P < 0.001) on receiver operating characteristics, with an optimal threshold of 6.25 (sensitivity 81.2%, specificity 73.4%). Of the individual components, only acid exposure time (AUC 0.799, P < 0.001), mean nocturnal baseline impedance (AUC 0.785, P < 0.001), and reflux episodes (AUC 0.764, P < 0.001) approached the Lyon score performance. The Lyon score segregated treatment response in both the European (AUC 0.908, P < 0.001) and Asian validation cohorts (AUC 0.637, P < 0.001) and outperformed the DeMeester score in sensitivity for predicting outcome in the developmental and Asian validation cohorts. DISCUSSION: The novel Lyon score segregates reflux phenotypes and identifies likelihood of symptom response from antireflux therapy.

1 September 2023 in American Journal of Gastroenterology
Verified
Journal Article
Closed access
Mentore RibolsiMentore Ribolsi
Mentore Ribolsi
LMLorenzo Marchetti
Lorenzo Marchetti
ESEdoardo Vincenzo Savarino
Edoardo Vincenzo Savarino
CGC. Prakash Gyawali
C. Prakash Gyawali
MCMichele Cicala
Michele Cicala
INTRODUCTION: Gastroesophageal reflux disease (GERD) severity increases with esophageal body hypomotility, but the impact of Chicago Classification (CC) v4.0 criteria on GERD diagnosis is incompletely understood. METHODS: In patients with GERD evaluated with high-resolution manometry and pH-impedance monitoring, CCv3.0 and CCv4.0 diagnoses were compared. RESULTS: In 247 patients, hypomotility diagnosis decreased from 45.3% (CCv3.0) to 30.0% (CCv4.0, P < 0.001). In contrast, within patients with ineffective esophageal motility, proportions with pathological acid exposure increased from 38% (CCv3.0) to 88% (CCv4.0); baseline impedance and esophageal clearance demonstrated similar findings (P < 0.05 for each comparison). DISCUSSION: CCv4.0 hypomotility criteria are more specific in supporting GERD evidence compared with CCv3.0.

1 March 2021 in Journal of Pharmaceutical and Biomedical Analysis
Verified
Journal Article
Closed access
SGSalvatore Genovese
Salvatore Genovese
Francesco EpifanoFrancesco Epifano
Francesco Epifano
LMLorenzo Marchetti
Lorenzo Marchetti
MBMaria Bastianini
Maria Bastianini
FCFabio Cardellini
Fabio Cardellini
SFSerena Fiorito
Serena Fiorito

24 June 2026 in American Journal of Gastroenterology
Verified
Journal Article
Closed access
MRMentore Ribolsi
Mentore Ribolsi
LMLorenzo Marchetti
Lorenzo Marchetti
CCChiara Catamo
Chiara Catamo
LGLaura Galdi
Laura Galdi
MDMarco Distefano
Marco Distefano
Michele CicalaMichele Cicala
Michele Cicala
Background: Acid exposure time (AET) is the reference metric quantifying esophageal acid burden, yet patients with pathological AET may fail to respond to PPI therapy. Given the logarithmic nature of pH, AET does not account for the exponential increase in hydrogen ion (H + ) concentration at lower pH values. Aim: To quantify acid burden using total integrated acidity exposure (TIAE), a dose-based metric integrating H + load over time, and to assess whether TIAE improves prediction of PPI response compared with conventional AET. Methods: Impedance-pH data were retrospectively evaluated. TIAE was calculated by integrating H + concentration (10 -pH ) at 1-second resolution across all acid reflux episodes. Diagnostic performance for PPI response was assessed using ROC analysis, multivariable logistic regression and decision curve analysis (DCA). Results: Among 174 patients (97 PPI responders, 77 non-responders), responders exhibited higher TIAE than non-responders and controls (p<0.0001). TIAE showed superior discrimination for PPI response compared with AET (AUC 0.78 vs 0.64). In multivariable models, TIAE independently predicted response both as a dichotomized and continuous variable, whereas continuous AET was not independently associated. TIAE correlated more strongly with MNBI than AET (ρ=-0.49 vs -0.26). DCA demonstrated greater net clinical benefit for models incorporating TIAE across clinically relevant threshold probabilities. In patients with inconclusive AET (4-6%), TIAE accurately segregated responders from non-responders. Very low pH (pH<2) greatly affected TIAE value and showed the strongest association with treatment response. Conclusions: Quantifying H + load provides a physiologically grounded assessment of esophageal acid burden and improves prediction of PPI response.

25 December 2023 in Alzheimer's & Dementia
Verified
Journal Article
Open access
EGElena Gatti
Elena Gatti
GSGiovanni Sgrò
Giovanni Sgrò
SFSerena Fiorito
Serena Fiorito
SGSalvatore Genovese
Salvatore Genovese
LMLorenzo Marchetti
Lorenzo Marchetti
SGSamantha Galluzzi
Samantha Galluzzi
Background: We designed a clinical trial to evaluate cognitive and biological effects of a 36‐week treatment with citrus peel extract in older adults with subjective cognitive decline (SCD) (ClinicalTrials.gov identifier: NCT04744922). Here we present baseline sociodemographic, clinical, and cognitive characteristics of the enrolled subjects.Method: Eighty subjects were enrolled between April 2021 and August 2022, and randomly assigned to receive either active treatment (400 mg citrus peel extract standardized in content of auraptene ‐ 0.1 mg ‐ and naringenin – 3 mg) or placebo in a 1:1 ratio for 36 weeks. Data about nutritional state and comorbidity, current therapy, health‐related behaviours, cognitive performance on verbal and non‐verbal memory, attention, executive and visuospatial functions were collected. Differences between groups (termed group A and B to avoid unblinding – the treatment allocation is unknown to the investigators) were compared using independent t‐test or Fisher’s exact test.Result: The enrolled subjects have a mean age of 69.2±4.3 years, a high level of education (mean 13.7±3.5 years) and a higher prevalence of females (75%), with no significant differences between groups A and B. Nutritional state and comorbidity were similar (Body Mass Index: 25.1±4.8 vs 24.0±3.9, p = .27 and Cumulative Illness Rating Scale: 1.46±0.22 vs 1.51±0.24, p = .38, groups A and B, respectively). The most frequent concurrent therapies included cardiovascular system and alimentary tract and metabolism drugs, with no significant differences between A and B (55% vs 63%, p = .32; 61% vs 66%, p = .41, respectively). Health‐related behaviours were also similar between A and B (Mediterranean Diet Adherence Screener: 9.0±1.9 vs 8.8±1.8; Smoking: 13% vs 8%; Alcohol consumption: wine 81% vs 83%, coffee consumption 93% vs 88%, all p = >.30). Cognitive scores were all within the normal range and similar between groups, except for the Wisconsin Card Sorting test total score, where group A performed marginally better than group B (27.9±21.6 vs 40.7±32.2, p = .049).Conclusion: The trial is expected to complete the longitudinal assessment in April 2023. The results of this trial will enable to evaluate the efficacy of citrus phytochemicals in SCD, informing the design of future nutritional interventions in people at risk of decline cognitive.